Insights from 2023 ASH Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASH 2023 Insights: "Asciminib + Imatinib, Nilotinib, or Dasatinib in Pts With Previously Treated Ph+ CML in Chronic or Accelerated Phase"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Jorge Cortés
By
Insights from 2023 ASH Annual Meeting
FEATURING
Jorge Cortés
Comments 0
Login to view comments.
Click here to Login
